Profile data is unavailable for this security.
About the company
Shanghai Allist Pharmaceuticals Co Ltd is a China-based company focusing on the field of tumor treatment. The Company has built a research and development pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. The Company has established a complete new drug research and development system, covering all aspects of lead drug discovery and optimization, candidate drug evaluation and establishment, drug preclinical and clinical research, drug registration and application, industrialization and commercialization. The Company has a number of research pipeline projects under development, such as vometinib. Its drugs are used in the fields of blood pressure reduction, anti-tumor, anti-diabetic and gastric acid related diseases.
- Revenue in CNY (TTM)2.48bn
- Net income in CNY915.35m
- Incorporated2004
- Employees1.04k
- LocationShanghai Allist Pharmaceuticals Co LtdZhangjiang Hightech ValleySHANGHAI 200023ChinaCHN
- Phone+86 2 151371858
- Fax+86 2 151320233
- Websitehttps://www.allist.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Junshi Biosciences Co Ltd | 1.63bn | -2.02bn | 25.08bn | 2.57k | -- | 4.23 | -- | 15.40 | -2.06 | -2.06 | 1.66 | 6.97 | 0.1348 | 1.05 | 4.11 | 634,034.10 | -18.18 | -18.87 | -23.17 | -23.11 | 64.05 | 69.13 | -134.86 | -88.41 | 1.91 | -215.80 | 0.3018 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Kangmei Pharmaceutical Co Ltd | 4.93bn | 160.40m | 25.79bn | 4.41k | 159.93 | 3.64 | -- | 5.23 | 0.0116 | 0.0116 | 0.3577 | 0.5117 | 0.34 | 1.40 | 2.43 | 1,118,464.00 | 1.12 | -17.60 | 1.69 | -32.24 | 22.71 | -72.78 | 3.28 | -101.19 | 0.8746 | -- | 0.0465 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.75bn | 928.37m | 25.99bn | 8.22k | 27.43 | 3.05 | -- | 2.97 | 0.6391 | 0.6391 | 6.02 | 5.76 | 0.4511 | 1.08 | 3.46 | 1,064,162.00 | 4.76 | 5.67 | 6.90 | 8.07 | 59.44 | 60.52 | 10.55 | 11.61 | 0.8451 | 5.48 | 0.5047 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Bluestar Adisseo Co | 13.53bn | 327.58m | 26.68bn | 2.73k | 81.46 | 1.77 | -- | 1.97 | 0.1222 | 0.1222 | 5.04 | 5.63 | 0.6286 | 4.67 | 7.33 | 4,947,799.00 | 1.52 | 5.28 | 1.85 | 6.94 | 23.81 | 30.31 | 2.42 | 8.76 | 1.04 | 4.30 | 0.1325 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Shanghai Allist Pharmaceuticals Co Ltd | 2.48bn | 915.35m | 27.99bn | 1.04k | 30.58 | 6.48 | -- | 11.27 | 2.03 | 2.03 | 5.52 | 9.60 | 0.6091 | 3.16 | 10.51 | 2,379,802.00 | 22.44 | 0.6405 | 24.19 | 0.6933 | 94.48 | 96.42 | 36.84 | 2.54 | 8.22 | -- | 0.0004 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
| Autobio Diagnostics Co Ltd | 4.50bn | 1.30bn | 29.37bn | 5.54k | 22.40 | 3.32 | -- | 6.53 | 2.24 | 2.24 | 7.74 | 15.11 | 0.4066 | 2.08 | 4.27 | 811,768.30 | 11.81 | 12.59 | 14.50 | 15.79 | 64.76 | 61.62 | 29.04 | 26.96 | 2.81 | -- | 0.1035 | 46.40 | 0.0457 | 18.15 | 4.28 | 16.70 | 17.03 | 11.32 |
| Gan & Lee Pharmaceuticals | 2.61bn | 386.85m | 29.63bn | 4.48k | 73.38 | 2.68 | -- | 11.35 | 0.6716 | 0.6716 | 4.52 | 18.38 | 0.234 | 0.8926 | 10.97 | 582,412.30 | 3.47 | 8.30 | 3.71 | 8.83 | 72.29 | 85.39 | 14.83 | 26.44 | 7.74 | -- | 0.0006 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
| Humanwell Healthcare Group Co Ltd | 24.67bn | 1.96bn | 31.44bn | 17.68k | 15.96 | 1.80 | -- | 1.27 | 1.21 | 1.21 | 15.25 | 10.73 | 0.6833 | 3.80 | 2.77 | 1,395,473.00 | 7.21 | 6.20 | 13.29 | 12.72 | 45.02 | 42.82 | 10.55 | 9.84 | 1.20 | 31.56 | 0.3293 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
Data as of Jun 07 2024. Currency figures normalised to Shanghai Allist Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
10.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 4.68m | 2.26% |
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Sep 2023 | 4.20m | 2.03% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 2.76m | 1.34% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 2.06m | 1.00% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 1.93m | 0.93% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.31m | 0.63% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 1.30m | 0.63% |
| The Vanguard Group, Inc.as of 09 May 2024 | 1.17m | 0.57% |
| China Fund Management Co., Ltd.as of 31 Dec 2023 | 747.08k | 0.36% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 724.77k | 0.35% |
More ▼
Data from 31 Dec 2023 - 06 Jun 2024Source: FactSet Research Systems Inc.
